Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00231569 · ClinicalTrials.gov registry record · Phase 2
Dose-escalating Safety Study in Subjects on Stable Statin Therapy
A Phase 2 study, sponsored by Kastle Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 74
- Enrollment target
NCT00231569 is a Phase 2 study that has completed, run by Kastle Therapeutics. The registered enrollment target is 74 participants.
The verdict
NCT00231569, a Phase 2 study, has completed, sponsored by Kastle Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 74 participants
- Enrollment target
Study Summary
The aim of this study is to assess the safety of varying doses of ISIS 301012 in subjects on Stable statin therapy.
Interventions
- DRUG ISIS 301012 or Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2005-09 |
| Est. Completion | 2007-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00231569
The ClinicalTrials.gov registry entry for NCT00231569 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kastle Therapeutics, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ISIS 301012 or Placebo is the first listed.
NCT00231569 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00231569 about?
NCT00231569 is a clinical study titled "Dose-escalating Safety Study in Subjects on Stable Statin Therapy". The aim of this study is to assess the safety of varying doses of ISIS 301012 in subjects on Stable statin therapy.
What is the current status of trial NCT00231569?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 74 participants. The study started on 2005-09. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00231569?
The interventions under investigation include: ISIS 301012 or Placebo (DRUG).
Who is sponsoring clinical trial NCT00231569?
This trial is sponsored by Kastle Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.